BlackRock, Inc. Amends Schedule 13G/A for 4D Molecular Therapeutics, Inc.

BlackRock, Inc. has filed an amendment to its Schedule 13G/A for 4D Molecular Therapeutics, Inc., reporting ownership of 3,062,596 shares, representing 6.6% of the company's common stock. The filing indicates that BlackRock has sole voting power over 2,988,740 shares and sole dispositive power over all 3,062,596 shares. The amendment reflects changes in ownership, with a decrease of 948,159 shares but an increase in the value of the holdings by $15,256,044.64. The filing also includes certifications that the securities were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer. The amendment is the fifth such filing by BlackRock for 4D Molecular Therapeutics, Inc.